News
EXOZ
9.88
+0.82%
0.08
Weekly Report: what happened at EXOZ last week (0504-0508)?
Weekly Report · 2d ago
eXoZymes announces graduation from Shell GameChanger Accelerator
TipRanks · 5d ago
eXoZymes Prepares Investor Presentation for Proposed Public Offering
TipRanks · 6d ago
Weekly Report: what happened at EXOZ last week (0427-0501)?
Weekly Report · 05/04 09:24
Weekly Report: what happened at EXOZ last week (0420-0424)?
Weekly Report · 04/27 09:25
Weekly Report: what happened at EXOZ last week (0413-0417)?
Weekly Report · 04/20 09:24
Weekly Report: what happened at EXOZ last week (0406-0410)?
Weekly Report · 04/13 09:25
Top Executive’s Surprise Stock Move Shakes Up eXoZymes Insider Activity
TipRanks · 04/11 02:03
eXoZymes Advances Toward Planned Securities Offering Preparation
TipRanks · 04/10 21:57
Exozymes CSO Tyler Korman disposes of USD 15,424 common shares
Reuters · 04/10 20:31
eXoZymes CCO says NCTx targets supplement launch for NCT, eyes pharma options
Reuters · 04/10 13:10
EXOZYMES INC - ANNOUNCES COMMON STOCK OFFERING - SEC FILING
Reuters · 04/09 21:01
Exozymes files Form 3 for Chief Commercial Officer Damien Perriman
Reuters · 04/08 23:20
Weekly Report: what happened at EXOZ last week (0330-0403)?
Weekly Report · 04/06 09:25
eXoZymes reports FY results
Seeking Alpha · 03/31 20:45
eXoZymes Inc. - Common Stock Q4 EPS $(0.31)
Benzinga · 03/31 20:36
eXoZymes Updates Investor Presentation for NCTx Business
TipRanks · 03/31 14:26
Earnings Scheduled For March 31, 2026
Benzinga · 03/31 11:11
Weekly Report: what happened at EXOZ last week (0323-0327)?
Weekly Report · 03/30 09:25
Exozymes set to host FY2025 results conference call; financial calendar updates
Reuters · 03/25 20:10
More
Webull provides a variety of real-time EXOZ stock news. You can receive the latest news about eXoZymes Inc through multiple platforms. This information may help you make smarter investment decisions.
About EXOZ
Invizyne Technologies, Inc. is a biotechnology, pre-revenue, development stage company. The Company's cell-free technology expands its ability to perform enzyme-based conversions, guiding towards sustainable biomanufacturing. The Company is primarily engaged in the development of the SimplePath platform. Its SimplePath platform consists of a series of enzyme based biomanufacturing systems that leverage natural processes to perform complex chemical conversions that convert a starting material into a desired end-product. Each SimplePath system is composed of one or more modules which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. It can provide solutions for natural ingredients (cannabinoids, flavor enhancers for food and beverage products, fragrances, nutraceuticals, organic compounds), pharmaceuticals (natural products with therapeutic properties) and chemicals (commodity chemicals, specialty chemicals, biofuels).